HOUSTON--(BUSINESS WIRE)--AbBC Therapies, Inc., the pioneer in the development of antibody-biological conjugates (AbBCs), today announced its participation in the upcoming 45th Annual Goldman Sachs Global Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Fla.
Ian Estepan, Executive Chairman of AbBC Therapies, will be presenting on June 11, 2024, at 4:00 p.m. ET. The presentation will highlight AbBC's proprietary targeted granzyme B immunotherapy (TGI) platform, which was designed to overcome limitations of current antibody drug conjugates (ADCs) and immunotherapies to deliver targeted therapies for a broad range of cancers and other diseases.
“We are excited to participate in the Goldman Sachs Global Healthcare Conference and showcase how AbBC technology combines the best attributes of ADCs and immunotherapies into a single molecule,” said Mr. Estepan. “Our TGI platform has the potential to greatly improve treatment by offering improved efficacy and reduced side effects for patients battling cancer and other devasting diseases.”
Key topics to be covered in the presentation include:
- The design of the TGI platform
- Preclinical data showcasing the efficacy and safety profile of AbBC’s TGI platform
- Development and value creation strategy
About AbBC Therapies
AbBC Therapies is developing a next-generation targeted therapeutic platform that combines the tumor targeting properties of ADCs with the granzyme B killing mechanism of immunotherapies into a single hybrid molecule. The Company’s proprietary platform is designed to overcome limitations of current ADCs and immunotherapies to deliver targeted therapies with improved efficacy and reduced side effects. The TGI platform consists of pipeline of seven products in development targeting ophthalmology and broad oncology indications. AbBC Therapies is committed to advancing its pipeline and with the goal of transforming the treatment landscape for patients with cancer and other devastating diseases.
